Every round on record, with the sources behind each and the investors on them.
RegCell develops therapies based on regulatory T cells (Treg) to treat autoimmune diseases.
regcellbio.comEmeryville, CABiotechFounded 2016
3 sources
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The $66 million figure includes Japanese government support; the source does not state a round stage, investors, valuation, financing total, or headquarters.
4 sources
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The page links to a separate story mentioning $45M in funding, but does not state that amount for this seed round.; not on the page it cites, so not applied: date
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A [ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $66M | 2026-09-15 | not stated | No recent discussion |
3 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 3 sources The $66 million figure includes Japanese government support; the source does not state a round stage, investors, valuation, financing total, or headquarters. | ||||
RegCell develops cell therapies that use epigenetically reprogrammed, antigen-specific regulatory T cells to restore immune tolerance for people with autoimmune diseases and transplantation challenges.
RegCell is targeting the central problem in autoimmune disease: existing therapies broadly suppress the immune system, can carry serious side effects, and often require lifelong treatment, while its platform is designed to convert disease-driving T cells into stable, antigen-specific regulatory T cells without gene engineering. The $44 million Series A led by Playground Global plus a roughly $22 million AMED grant is intended to fund an IND submission, clinical proof of concept, and a second autoimmune program through Phase 2, making the bet a move from Nobel-linked immunology toward scalable clinical therapy.
Checked against 10 sources today
| Seed [ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | n/a | 2025-03-18 | Fast Track Initiative (FTI), The University of Tokyo Edge Capital Partners | No recent discussion |
4 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 4 sources The page links to a separate story mentioning $45M in funding, but does not state that amount for this seed round.; not on the page it cites, so not applied: date [ BUILT WITH ]·[ SEARCH ]found by the research agent·[ SCRAPE ]4 pages read: regcellbio.com, prnewswire.com, fti.vc·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 of 4 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
Also named as backers in company research: Japan Agency for Medical Research and Development (AMED), Playground Global, Global Brain, 321FORCE Global Innovation Fund L.P., Mitsui Chemicals Group, LG Technology Ventures, Alumni Ventures, Medical Incubator Japan